KdT Ventures

We’re excited to announce the close of our oversubscribed $100M Fund IV to invest in early-stage frontier science companies! 🎉🎉 Congrats to the team and Phil Grayeski Ph.D., who got promoted to Managing Partner and Patrick Malone, MD PhD , to Partner. 🔥🔥 Excited for the future and sharing our release here: https://lnkd.in/eXhrdxTn

KdT Ventures portfolio company Dyno Therapeutics announces their expanded partnership with Roche- designing and delivering AAV capsids to translate the promise of generic medicine for patients in need. Congratulations on this milestone!

Great opportunity for scientist-entrepreneurs interested in building a neuro-focused startup!

FirstWord Pharma covers our recent news: The adoption of AI tools in drug development has surged this year, but Cain McClary, MD has been betting on the technology since "day one" of KdT Ventures, which he founded in 2017. The firm closed its fourth fund at $100 million on Wednesday — bringing its total assets to $250 million — with plans to back early-stage startups that exist at the intersection of data science and life science. "The ability to leverage AI to accelerate compound identification, optimise clinical trials, and predict drug interactions has transformative potential in biotech," McClary told FirstWord. Read the article by Elizabeth Eaton: https://lnkd.in/efENAKWc

Venture Capital Journal reporter Iris Dorbian covers today’s news: https://lnkd.in/ewWa6_Yq

Kyle LaHucik at Endpoints News speaks with Cain McClary, MD. The KdT team thinks of itself as the third, fourth and fifth employee at many of its portfolio companies, McClary said, so the firm didn’t want to drastically grow its fund size beyond its recent efforts. “Our special sauce and core competency is really that zero-to-one step of these companies, and the feeling at the firm is that potentially when you have a much larger asset base, you are distracted by the later and larger checks,” McClary said. https://lnkd.in/dnCZuXqE

Austin Business Journal speaks with Cain McClary, MD about our recent fund close. "KdT's investments include a range of companies, though most of its portfolio is in the digital health and therapeutics realm. It often aims to be the first institutional investor in science-driven startups, and it typically cuts checks ranging from $500,000 to $5 million." Read the article: https://lnkd.in/dhiKgTAT

Thanks The Wall Street Journal for speaking with Cain McClary, MD and Mack Healy about the close of our fourth fund and what's next. KdT Ventures has secured just over $100 million for its fourth venture fund targeting startups applying computational tools and technology to sectors such as #healthcare, #chemicals and #agriculture. Advances in #AI and biological sciences promise to enable products and services across various industries. KdT has a team of investors with advanced degrees and experience to spot such convergence opportunities. Sharing the article by Brian Gormley: https://lnkd.in/dgUgtXDD

As a father, husband, son, and scientist I dream of a world where no neurological disease is beyond our reach, where we don't shy away from targets because they seem too risky. A world where every neurological disease, no matter how tough, is druggable. Today, with the unveiling of Montara Therapeutics, Inc., I hope to contribute to making that dream a reality.  At my previous company, Mitokinin, we worked for nearly a decade to develop a potential disease-modifying treatment for Parkinson's disease. During that process, I learned how difficult it is to generate safe and effective drugs for many of the neurological diseases that millions suffer from worldwide. After Mitokinin was acquired last fall, I knew that I wanted to start a new company to address some of the other tough-to-drug neurological indications, including Alzheimer's disease, brain cancers, and neuropsychiatric indications. When Kevan Shokat, who was my Ph.D. supervisor University of California, San Francisco and scientific co-founder of Mitokinin, came to me with new research from his lab suggesting a pharmacological mechanism to block drugs from working in the periphery, thereby mitigating their adverse side effects, I immediately recognized the impact this could have, not for the treatment of just one or two diseases, but across nearly all neurodegenerative and neurological diseases and brain cancer.  Together, with the help of our other scientific co-founders, Martin Kampmann and Thomas Südhof, a highly experienced team of advisors, as well as nine stellar employees from Mitokinin, we formed Montara Therapeutics to progress this groundbreaking research from bench to bedside, developing safer and more efficacious treatments for various diseases of the brain. Today, we’re thrilled to announce the funding of our seed round. With support from top-tier investors, including SV Dementia Discovery Fund (DDF), Two Bear Capital, KdT Ventures, and Dolby Family Ventures, I believe we have the right ingredients to accomplish our mission, and I’m very excited for what the future has in store for Montara, but most importantly, for patients We look forward to sharing more details in the months to come. Follow Montara Therapeutics, Inc. to stay updated on our progress. Thanks to Amber Tong and Endpoints News for the exclusive!

Like this song did 13 years ago, ZymoChem just dropped the BAYSE. https://lnkd.in/ezWHTNX7